| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/9/2025 | $7.00 | Neutral → Underweight | Analyst |
| 1/14/2025 | Mkt Perform → Outperform | William Blair | |
| 9/10/2024 | $14.00 | Overweight | Cantor Fitzgerald |
| 7/11/2024 | $18.00 → $12.00 | Buy | Lake Street |
| 5/1/2024 | $30.00 → $23.00 | Buy | Craig Hallum |
| 5/1/2024 | Outperform → Mkt Perform | William Blair | |
| 5/1/2024 | $36.00 → $13.00 | Overweight → Neutral | JP Morgan |
| 1/31/2023 | $20.00 | Buy | Lake Street |
| 7/18/2022 | $15.00 | Buy | Craig Hallum |
| 7/26/2021 | Outperform | William Blair |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Analyst downgraded CVRx, Inc. from Neutral to Underweight and set a new price target of $7.00
William Blair upgraded CVRx, Inc. from Mkt Perform to Outperform
Cantor Fitzgerald initiated coverage of CVRx, Inc. with a rating of Overweight and set a new price target of $14.00
Lake Street reiterated coverage of CVRx, Inc. with a rating of Buy and set a new price target of $12.00 from $18.00 previously
Craig Hallum resumed coverage of CVRx, Inc. with a rating of Buy and set a new price target of $23.00 from $30.00 previously
JP Morgan downgraded CVRx, Inc. from Overweight to Neutral and set a new price target of $13.00 from $36.00 previously
William Blair downgraded CVRx, Inc. from Outperform to Mkt Perform
Lake Street initiated coverage of CVRx, Inc. with a rating of Buy and set a new price target of $20.00
Craig Hallum initiated coverage of CVRx, Inc. with a rating of Buy and set a new price target of $15.00
William Blair initiated coverage of CVRx, Inc. with a rating of Outperform
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Fastest customizable press release news feed in the world
4 - CVRx, Inc. (0001235912) (Issuer)
3 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
10-Q - CVRx, Inc. (0001235912) (Filer)
8-K - CVRx, Inc. (0001235912) (Filer)
8-K - CVRx, Inc. (0001235912) (Filer)
SD - CVRx, Inc. (0001235912) (Filer)
10-Q - CVRx, Inc. (0001235912) (Filer)
8-K - CVRx, Inc. (0001235912) (Filer)
DEF 14A - CVRx, Inc. (0001235912) (Filer)
DEFA14A - CVRx, Inc. (0001235912) (Filer)
8-K - CVRx, Inc. (0001235912) (Filer)
SCHEDULE 13D/A - CVRx, Inc. (0001235912) (Subject)
MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2025. Recent Highlights Total revenue for the second quarter 2025 was $13.6 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) revenue for the second quarter of 2025 was $12.1 million, an increase of 15% over the prior year quarterActive implanting centers in the U.S. grew to 240, an increase of 27% since June 30, 2024CMS propo
MINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 3:00pm Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at ir.cvrx.com. About CVRx, Inc. CVRx is a commercial-stage me
MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2025 financial and operating results after market close on Monday, August 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, plea
MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim implant procedure as part of the New Technology Ambulatory Payment Classification (APC) 1580, with an associated payment of approximately $45,000 for procedures performed in the outpatient setting. CMS is also soliciting comments about the need for a Level 6 Neurostimulator APC. We expect CMS will publish the 2026 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule in November, which is expected to take effect on January 1, 2026. This pro
MINNEAPOLIS, May 28, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025. The Company is scheduled to present at 10:00am Central Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at ir.cvrx.com. About CVRx, Inc. CVRx is a commercial-stage medical device co
MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2025. Recent Highlights Total revenue for the first quarter 2025 was $12.3 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) revenue for the first quarter of 2025 was $11.1 million, an increase of 14% over the prior year quarterActive implanting centers in the U.S. grew to 227, an increase of 19% since March 31, 2024Real-world e
MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-800-445-7795 for U.S. callers, or 1-785-424-1699 for international callers, approximately ten minutes prior to the start time
MINNEAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited first quarter 2025 revenue results. "While we continue to make significant progress in driving adoption of Barostim, first quarter revenue fell short of our expectations," said Kevin Hykes, President and Chief Executive Officer of CVRx. "A core element of the commercial strategy initiated last year has been to build a world-class sales organization. As part of this effort, we brought in a number of new high-quality sales representatives in the back half of 2024 and the first quarter of 2025. We are thrilled with the lev
MINNEAPOLIS, Feb. 12, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today the presentation of new real-world evidence at the Technology and Heart Failure Therapeutics (THT) conference in Boston. The study demonstrated large and statistically significant reductions in hospital visits (hospitalizations and emergency department visits) and length of stay after Barostim implantation, compared to before. The research was published simultaneously and is available now in the Journal of Cardiac Failure. "Despite contemporary medications, the clinical and economic burden of heart failure remains unacceptably high. This new study sh
MINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2024. Recent Highlights Total revenue for the fourth quarter of 2024 was $15.3 million, an increase of 36% over the prior year quarterU.S. Heart Failure (HF) revenue for the fourth quarter of 2024 was $14.3 million, an increase of 41% over the prior year quarterTotal revenue for 2024 was $51.3 million, an increase of 31% over the prior yearActive implanti
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
Live Leadership Updates
MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company's US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and establishing Barostim as standard of care in the United States. "We are thrilled to welcome Robert to the CVRx executive team as we continue to expand the adoption of Barostim therapy," said Kevin Hykes, President and CEO of CVRx. "Robert is well-known and respected within the heart failure community and
Appointment effective February 12 following Nadim Yared's retirement Hykes currently serves as Augmedics' President and CEO, and has served on CVRx's Board of Directors since 2022 MINNEAPOLIS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company's new President and Chief Executive Officer, effective February 12. Hykes will continue to serve on the Company's Board of Directors. Yared will retire from the Company and resign his Board seat concurrent with Hykes' appointment and has agreed to consult with the Company to ensure a seamless transition. Hykes is an accomplishe
MINNEAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Kevin Hykes will join its Board of Directors effective December 21, 2022. "We are excited to welcome an executive with the depth of expertise of Kevin Hykes to our Board of Directors," said John Nehra, lead independent director of CVRx. "His commercial experience in accelerating the growth of novel interventional therapies and his executive acumen will prove an invaluable resource as we continue to build our b
Live finance-specific insights
MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2025. Recent Highlights Total revenue for the second quarter 2025 was $13.6 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) revenue for the second quarter of 2025 was $12.1 million, an increase of 15% over the prior year quarterActive implanting centers in the U.S. grew to 240, an increase of 27% since June 30, 2024CMS propo
MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2025 financial and operating results after market close on Monday, August 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, plea
MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2025. Recent Highlights Total revenue for the first quarter 2025 was $12.3 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) revenue for the first quarter of 2025 was $11.1 million, an increase of 14% over the prior year quarterActive implanting centers in the U.S. grew to 227, an increase of 19% since March 31, 2024Real-world e
MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-800-445-7795 for U.S. callers, or 1-785-424-1699 for international callers, approximately ten minutes prior to the start time
MINNEAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited first quarter 2025 revenue results. "While we continue to make significant progress in driving adoption of Barostim, first quarter revenue fell short of our expectations," said Kevin Hykes, President and Chief Executive Officer of CVRx. "A core element of the commercial strategy initiated last year has been to build a world-class sales organization. As part of this effort, we brought in a number of new high-quality sales representatives in the back half of 2024 and the first quarter of 2025. We are thrilled with the lev
MINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2024. Recent Highlights Total revenue for the fourth quarter of 2024 was $15.3 million, an increase of 36% over the prior year quarterU.S. Heart Failure (HF) revenue for the fourth quarter of 2024 was $14.3 million, an increase of 41% over the prior year quarterTotal revenue for 2024 was $51.3 million, an increase of 31% over the prior yearActive implanti
MINNEAPOLIS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2024 financial and operating results after market close on Tuesday, February 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to t
MINNEAPOLIS, Oct. 29, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the third quarter of 2024. Recent Highlights Total revenue for the third quarter 2024 was $13.4 million, an increase of 27% over the prior year quarterU.S. Heart Failure (HF) revenue for the third quarter of 2024 was $12.2 million, an increase of 30% over the prior year quarterActive implanting centers in the U.S. were 208, an increase of 31% over the prior year quarterFinal I
MINNEAPOLIS, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release third quarter 2024 financial and operating results after market close on Tuesday, October 29, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to th
MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2024. Recent Highlights Total revenue for the second quarter 2024 was $11.8 million, an increase of 24% over the prior year quarterU.S. Heart Failure (HF) revenue for the second quarter of 2024 was $10.5 million, an increase of 27% over the prior year quarterActive implanting centers in the U.S. were 189, an increase of 35% over the second quarter of 2023
This live feed shows all institutional transactions in real time.
SC 13D/A - CVRx, Inc. (0001235912) (Subject)
SC 13G/A - CVRx, Inc. (0001235912) (Subject)
SC 13G/A - CVRx, Inc. (0001235912) (Subject)
SC 13G/A - CVRx, Inc. (0001235912) (Subject)
SC 13D/A - CVRx, Inc. (0001235912) (Subject)
SC 13D/A - CVRx, Inc. (0001235912) (Subject)
SC 13G/A - CVRx, Inc. (0001235912) (Subject)
SC 13G - CVRx, Inc. (0001235912) (Subject)
SC 13G/A - CVRx, Inc. (0001235912) (Subject)
SC 13G - CVRx, Inc. (0001235912) (Subject)